Immuno-oncology therapies have revolutionized the treatment of many cancers over the last decade, where its unprecedented rise was driven by the success of immune checkpoint inhibitors (CPIs) such as PDLi antibody therapies and CAR-T cell therapies. In 2021, Cowen Research valued the CPI market at $34B (20% of the oncology market) and provided expectations that the market will increase to $64B by 2027. Despite continued promising results, the success of cancer immunotherapy in solid tumors have been limited due to several barriers. What obstacles remain to transform outcomes for patients with solid tumors? This session provides an overview of the innovations under development for improved solid tumor immunotherapy.